Evidence map›Paper›PMID 42023103›Full record

ArticleFrontiers in medicine2026

Effect of intravenous immunoglobulin combined with azithromycin sequential therapy on clinical outcomes and immune response in children with

Huiqing Guo

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Huiqing GuoOutpatient Department of Pediatrics, Children's Hospital of Shanxi and Women Health Center of Shanxi, Taiyuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: This single-center retrospective, non-randomized cohort study included 140 children diagnosed with MPP between January 2020 and February 2022. Patients received either azithromycin sequential therapy alone (control group, Results: The total effective rate was higher in the IVIG group than in the control group (97.14% vs. 84.29%, Conclusion: Adjunctive IVIG combined with azithromycin was associated with improved clinical and laboratory outcomes in children with MPP without increasing adverse events. Findings should be interpreted cautiously due to the retrospective design and potential residual confounding.

Indexed as

azithromycinchildrenclinical efficacyintravenous immunoglobulinMycoplasma pneumoniae pneumoniasequential therapy

Identifiers

PMID42023103
PMCPMC13095533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.